Clinical Trials Browser

Phase 2 × Active not recruiting × Maintenance × Clear all

NCT07199855 2025-09-30

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

Phase 2 Active not recruiting

Burkitt Lymphoma